ENTYVIO® ACCESS PROGRAM
The ENTYVIO Access Program provides approved ENTYVIO IV dose schedules1 not currently reimbursed on the Pharmaceutical Benefits Scheme (PBS).2 Under the program, ENTYVIO vials are provided free of charge by Takeda Australia. The program is restricted to IV ENTYVIO doses only – no additional doses are approved for ENTYVIO subcutaneous injections.
Please note: The program coordinator may contact you to request further information regarding your request. If you need to report an adverse event, please contact Takeda via email: AE.ANZ@takeda.com.
FREQUENTLY ASKED QUESTIONS
-
Tab contentApply online at www.entyvioaccess.com.au
If you have trouble accessing the portal due to institutional restrictions, you can use the digital request form which does not require any registration or login to use. Simply click on the link provided, https://entyvioaccess.com.au/supplyrequest, fill in the patient’s details and click submit. Alternatively, please request the interactive PDF request form, available on request from the program coordinator.
ENTYVIO® is indicated for the treatment of adult patients with moderate to severe ulcerative colitis or moderate to severe Crohn’s disease, who have had an inadequate response with, lost response to, or are intolerant to either conventional therapy or a TNFα antagonist.
PBS Information: Authority required. Refer to PBS for full details.
CLICK HERE TO REVIEW FULL APPROVED PRODUCT INFORMATION BEFORE PRESCRIBING.
Abbreviations: CD, Crohn’s disease; UC, ulcerative colitis; IV, intravenous; TNF, tumor necrosis factor.
ENTYVIO®, the ENTYVIO Logo® are registered trademarks of Millennium Pharmaceuticals, Inc., a Takeda company.
REFERENCES:
- ENTYVIO Product Information.
- Pharmaceutical Benefits Scheme. ENTYVIO 300 mg vial.www.pbs.gov.au/medicine/item/10384M-10390W-10398G-10415E [accessed Sep 2024].